Literature DB >> 16298821

Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.

Fadi I Jabr1.   

Abstract

Acute tumor lysis syndrome (ATLS) is a well-known complication of chemotherapy in patients with rapidly proliferative hematopoietic malignancies such as lymphoma and leukemia. Rituximab anti-CD20 monoclonal antibody, an alternative to chemotherapy in the treatment of low-grade follicular lymphoma, also has been associated with ATLS. Rituximab-induced ATLS has been reported in 2 patients with chronic lymphocytic leukemia and in 2 patients with non-Hodgkin's lymphoma. I report another case of rituximab-induced ATLS in a patient with diffuse large B-cell lymphoma and review the cases in the literature.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16298821     DOI： 10.1532/IJH97.NA0504

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  8 in total

Review 1.  Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.

Authors:  R O Dillman
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

2.  Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.

Authors:  Yasser Abou Mourad; Ali Taher; Ali Shamseddine
Journal:  Hematol J       Date:  2003

3.  Rituximab: Mechanism of action and resistance.

Authors:  David G Maloney; Barbara Smith; Andrea Rose
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

4.  Acute tumor lysis syndrome in non-Hodgkin lymphoma induced by dexamethasone.

Authors:  K Dhingra; S R Newcom
Journal:  Am J Hematol       Date:  1988-10       Impact factor: 10.047

5.  Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Authors:  H Yang; M H Rosove; R A Figlin
Journal:  Am J Hematol       Date:  1999-12       Impact factor: 10.047

6.  Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma.

Authors:  L F Cohen; J E Balow; I T Magrath; D G Poplack; J L Ziegler
Journal:  Am J Med       Date:  1980-04       Impact factor: 4.965

7.  Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

Authors:  J Bienvenu; R Chvetzoff; G Salles; C Balter; H Tilly; R Herbrecht; P Morel; P Lederlin; P Solal-Celigny; B Audhuy; B Christian; J Gabarre; O Casasnovas; G Marit; C Sebban; B Coiffier
Journal:  Hematol J       Date:  2001

8.  Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

Authors:  M Jensen; U Winkler; O Manzke; V Diehl; A Engert
Journal:  Ann Hematol       Date:  1998 Jul-Aug       Impact factor: 3.673
  8 in total
  4 in total

1.  Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma.

Authors:  Zaher K Otrock; Hassan A Hatoum; Ziad M Salem
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

2.  Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study.

Authors:  Theresa H M Keegan; Laura A McClure; James M Foran; Christina A Clarke
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

3.  Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP.

Authors:  Nina Sørensen; Paw Jensen; Erik Clasen-Linde; Jacob Moesgaard Larsen; Tarec El-Galaly
Journal:  Clin Case Rep       Date:  2018-01-26

Review 4.  Tumor lysis syndrome in childhood malignancies.

Authors:  Wing Lum Cheung; Kam Lun Hon; Cheuk Man Fung; Alexander Kc Leung
Journal:  Drugs Context       Date:  2020-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.